Clinical Trials at University of Cincinnati Cancer Center-UC Medical Center

As of June 2026, 55 paid clinical trials are recruiting at University of Cincinnati Cancer Center-UC Medical Center, located at 231 ALBERT SABIN WAY, ROOM 4110, CINCINNATI, OH 45267-0212, phone (513) 558-4592 in Cincinnati, Ohio. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

55 clinical trials at University of Cincinnati Cancer Center-UC Medical Center

·Clear filters·↓ Download CSV

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

for Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Drug: Bevacizumab

604 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04181060·Phase 3·Recruiting

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

Drug: Apalutamide

342 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

for Prostate Adenocarcinoma

Drug: Apalutamide

345 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT04134260·Phase 3·Recruiting

Apply to this trial

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

for Malignancy

626 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: All ages

Code: NCT04242095·Recruiting

Apply to this trial

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

for Clinical Stage I Esophageal Adenocarcinoma AJCC v8

95 locations incl. Phoenix

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT03801876·Phase 3·Recruiting

Apply to this trial

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

for Bladder Adenocarcinoma

Drug: Cabozantinib

578 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03866382·Phase 2·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

275 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT03739814·Phase 2·Recruiting

Apply to this trial

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

for Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

140 locations incl. Tucson

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT03493425·Phase 2·Recruiting

Apply to this trial

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

for Castration Levels of Testosterone

334 locations incl. Gilbert

Sponsor: SWOG Cancer Research Network

Sex: Male·Age: 18+

Code: NCT03678025·Phase 3·Recruiting

Apply to this trial

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

for Cardiotoxicity

577 locations incl. Anchorage

Sponsor: SWOG Cancer Research Network

Sex: All·Age: 18+

Code: NCT03418961·Phase 3·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

for B Acute Lymphoblastic Leukemia

455 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18 - 39

Code: NCT03150693·Phase 3·Recruiting

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

676 locations incl. Birmingham

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

780 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

Drug: Atezolizumab

338 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting

Apply to this trial